NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

XTL Biopharmaceuticals Ltd. (XTLB) Stock Analysis

XTL Biopharmaceuticals Ltd. (XTLB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

XTLB

$2.53

+$0.03 (+1.20%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XTLB with… →

XTLB Key Statistics

As of Sep 4, 2026
Trading
Open
$2.43
Previous Close
$2.50
Day's Range
2.43–2.53
52-Week Range
2.01–10.28
Volume
1.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.45
Valuation
Market Cap
$6.22M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.27
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.36
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$6.97M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.46M
1-Year Return
−49.40%
Dividend and dates
Avg Volume
71.06K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XTLB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+9.05%
2025−71.43%
2024+100.99%
2023−16.53%
2022−56.32%
2021−8.58%
2020+121.17%
2019−20.81%
2018−24.45%
2017−27.30%
2016 (partial year)−47.06%

As of September 4, 2026.

XTLB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$6.97M—
2024$0.00−$1.03M—
2023$0.00−$1.78M—
2022$0.00−$1.35M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00$0.00−$1.38M−$6.97M—
2024$0.00$0.00−$775.00K−$1.03M—
2023$0.00$0.00−$765.00K−$1.78M—
2022$0.00$0.00−$880.00K−$1.35M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XTLB Valuation vs Biotechnology Median

Median of 656 stocks
MetricXTLBBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values XTL Biopharmaceuticals Ltd. (XTLB) at $6.22M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 4.

The most recent close on file for XTLB is $2.53, dated September 4, 2026. That is +$0.03 (+1.20%) against the previous close. The 52-week range on file runs from $2.01 to $10.28. The latest close sits 25.87% above that 52-week low.

Financial Health

In fiscal 2025, XTL Biopharmaceuticals Ltd. reported revenue of $0.00. The same year closed with a net loss of $6.97M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.36.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.27.

Over the trailing twelve months the price has returned −49.40%. Measured over 10 years, that is −18.68% a year compounded. The reported beta is 0.45. Daily returns over the trailing 10 years annualize to a volatility of 103.33%.

Growth & Income

No dividend is on file for XTLB.

2026 is still running; the price is +9.05% year to date. Across the complete calendar years on file, 2020 returned +121.17% and 2025 returned −71.43%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

XTL Biopharmaceuticals Ltd. (XTLB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
XTL Biopharmaceuticals Ltd. XTLB $6.22M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. XTL Biopharmaceuticals Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.

Visit website →